曲妥珠單抗 Emtansine 市場按適應症、濃度、年齡層、最終用戶、通路和地區分類

Trastuzumab Emtansine Market, By Indication, By Strength, By Age Group, By End User, By Distribution Channel, By Geography

出版日期: 2025年08月14日 | 出版商:

Coherent Market Insights | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

曲妥珠單抗美坦市場規模預計在 2025 年為 25.4 億美元，預計到 2032 年將達到 45.5 億美元，2025 年至 2032 年的複合年成長率為 8.7%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	25.4億美元
效能數據	2020年至2024年	預測期	2025年至2032年
預測期：2025-2032年複合年成長率：	8.70%	2032年的價值預測	45.5億美元

全球曲妥珠單抗-美坦辛市場在癌症治療領域佔據重要地位，專注於用於治療 HER2 陽性乳癌的創新抗體藥物複合體(ADC)。曲妥珠單抗-美坦辛結合了曲妥珠單抗的靶向特異性和美坦辛的細胞毒性，透過將化療直接輸送至癌細胞，同時最大限度地降低全身毒性，從而實現精準醫療。這項治療方法進展徹底改變了 HER2 陽性轉移性乳癌患者的治療模式，尤其是對於先前接受過曲妥珠單抗或紫杉烷類藥物治療的患者。

這個市場涉及各種相關人員，包括製藥商、醫療保健提供者、監管機構和患者權益團體，他們都為這種救命療法的開發和廣泛應用做出了貢獻。隨著個人化醫療在腫瘤學領域持續受到關注，曲妥珠單抗美坦西林代表著朝著更有針對性和更有效的治療性介入的演變。全球市場動態受到多種因素的影響，例如乳癌發生率的上升、人們對 HER2 檢測認知的提高、新興市場醫療保健基礎設施的擴大以及正在進行的探索聯合治療和擴大適應症的臨床研究，這些因素使該市場成為更廣泛的腫瘤藥物領域的重要貢獻者。

市場動態

曲妥珠單抗-美坦辛的全球市場受到多個強勁促進因素的支撐，這些因素在國際醫療體系中持續擴張。主要促進因素是全球 HER2 陽性乳癌的發生率不斷上升，約佔全球乳癌患者的 20-25%。診斷能力的提升和 HER2 檢測通訊協定的廣泛應用顯著改善了患者識別和治療方法選擇，直接促進了市場成長。曲妥珠單抗-美坦辛的療效優於傳統化療方案，關鍵臨床試驗已證明其改善了患者的無惡化存活期和總存活率，這持續推動著醫生對該藥物的採用和患者的需求。

然而，該市場面臨重大限制因素，阻礙了其廣泛普及和採用。曲妥珠單抗 emtansine 的治療費用極高，通常每位患者每年超過 10 萬美元，對醫療保健系統、保險提供者和患者構成了重大財務障礙，尤其是在醫療保健預算有限的新興經濟體中。嚴格的監管核准流程和複雜的製造要求對市場進入和供應鏈挑戰構成了障礙。此外，血小板減少、肝毒性和心臟功能障礙等潛在副作用需要仔細監測患者，並可能限制治療合格。儘管有這些挑戰，但隨著適應症從轉移性乳癌擴展到輔助性治療和 HER2 陽性惡性腫瘤（如胃癌），仍然存在巨大的商業機會。生物相似藥的開發提供了降低成本和擴大市場進入的機會，而與免疫療法和其他標靶藥物的聯合治療策略則有可能改善結果並擴大不同患者群體的市場。

本次調查的主要特點

本報告對全球曲妥珠單抗美坦辛市場進行了詳細分析，並以 2024 年為基準年，展示了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%）。
它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
它根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，介紹了全球曲妥珠單抗 Emtansine 市場的主要企業概況。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興車型、市場擴張和行銷策略做出明智的決策。
全球曲妥珠單抗 Emtansine 市場報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過用於分析全球曲妥珠單抗 Emtansine 市場的各種策略矩陣來更輕鬆地做出決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 2.54 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	8.70%	2032 Value Projection:	USD 4.55 Bn

The global trastuzumab emtansine market represents a critical segment within the oncology therapeutics landscape, focusing on an innovative antibody-drug conjugate (ADC) designed to treat HER2-positive breast cancer. Trastuzumab emtansine combines the targeted specificity of trastuzumab with the cytotoxic potency of emtansine, creating a precision medicine approach that delivers chemotherapy directly to cancer cells while minimizing systemic toxicity. This therapeutic advancement has revolutionized treatment paradigms for patients with HER2-positive metastatic breast cancer, particularly those who have previously received trastuzumab and taxane-based therapies.

The market encompasses various stakeholders including pharmaceutical manufacturers, healthcare providers, regulatory bodies, and patient advocacy groups, all contributing to the development and accessibility of this life-saving treatment. As personalized medicine continues to gain prominence in oncology, trastuzumab emtansine exemplifies the evolution toward more targeted, effective therapeutic interventions. The global market dynamics are influenced by factors such as increasing breast cancer incidence rates, growing awareness of HER2 testing, expanding healthcare infrastructure in emerging markets, and ongoing clinical research exploring combination therapies and expanded indications, positioning this market as a significant contributor to the broader oncology pharmaceutical sector.

Market Dynamics

The global trastuzumab emtansine market is propelled by several robust drivers that continue to fuel its expansion across international healthcare systems. The primary driver remains the increasing global incidence of HER2-positive breast cancer, affecting approximately 20-25% of all breast cancer patients worldwide, creating a substantial patient population requiring targeted therapeutic interventions. Enhanced diagnostic capabilities and widespread implementation of HER2 testing protocols have significantly improved patient identification and treatment selection, directly contributing to market growth. The superior efficacy profile of trastuzumab emtansine compared to conventional chemotherapy regimens, demonstrated through pivotal clinical trials showing improved progression-free survival and overall survival rates, continues to drive physician adoption and patient demand.

However, the market faces considerable restraints that challenge widespread accessibility and adoption. The exceptionally high cost of trastuzumab emtansine treatment, often exceeding US$ 100,000 annually per patient, creates significant financial barriers for healthcare systems, insurance providers, and patients, particularly in developing economies with limited healthcare budgets. Stringent regulatory approval processes and complex manufacturing requirements contribute to market entry barriers and supply chain challenges. Additionally, potential adverse effects including thrombocytopenia, hepatotoxicity, and cardiac dysfunction require careful patient monitoring and may limit treatment eligibility. Despite these challenges, substantial opportunities emerge from expanding indications beyond metastatic breast cancer, including adjuvant settings and other HER2-positive malignancies such as gastric cancer. Biosimilar development presents opportunities for cost reduction and increased market access, while combination therapy strategies with immunotherapies and other targeted agents offer potential for enhanced therapeutic outcomes and market expansion in diverse patient populations.

Key features of the study

This report provides in-depth analysis of the global trastuzumab emtansine market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global trastuzumab emtansine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Genentech Inc., Zydus Cadila, Formosa Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global trastuzumab emtansine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global trastuzumab emtansine market.

Market Segmentation

Indication Insights (Revenue, USD Bn, 2020 - 2032)
- HER2-Positive, Metastatic Breast Cancer (MBC)
- HER2-Positive Early Breast Cancer (EBC)
Strength Insights (Revenue, USD Bn, 2020 - 2032)
- 100 mg per vial
- 160 mg per vial
Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Adult
- Geriatric
End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Cancer Treatment Centers
- Specialty Clinics
- Homecare Settings
- Others (Research Institutes)
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Genentech Inc.
- Zydus Cadila
- Formosa Pharmaceuticals
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Shanghai JMT-Bio Inc.
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Trastuzumab Emtansine Market, By Indication
- Global Trastuzumab Emtansine Market, By Strength
- Global Trastuzumab Emtansine Market, By Age Group
- Global Trastuzumab Emtansine Market, By End User
- Global Trastuzumab Emtansine Market, By Distribution Channel
- Global Trastuzumab Emtansine Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Trastuzumab Emtansine Market, By Indication, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
HER2-Positive, Metastatic Breast Cancer (MBC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
HER2-Positive Early Breast Cancer (EBC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Trastuzumab Emtansine Market, By Strength, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
100 mg per vial
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
160 mg per vial
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Trastuzumab Emtansine Market, By Age Group, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Trastuzumab Emtansine Market, By End User, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Cancer Treatment Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others (Research Institutes)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Trastuzumab Emtansine Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Trastuzumab Emtansine Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Strength, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

10. Competitive Landscape

Genentech Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Zydus Cadila
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Formosa Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Shanghai JMT-Bio Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies